Optimizing a DLL3-Targeted Radiotherapeutic Through Preclinical Development

• Explore the preclinical development of a DLL3-targeted radiotherapeutic from candidate design through efficacy evaluation
• Assess how biodistribution, tumor uptake & retention inform optimization of radiotherapeutic performance
• Leverage preclinical findings to guide candidate selection & progression towards clinical development

Novel Target

Speakers:

Anneli Savinainen

Vice President & Head of Preclinical Development

Mariana Oncology